Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HK2 | P52789 | 5/20 | 0.53 |
| ▸ | HK1 | P19367 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31343127 | 1.00 | LMNA (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL8655831 | 1.00 | LMNA (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL31754235 | 1.00 | LMNA (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL15686248 | 0.84 | HK2 (0.40) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL31507892 | 0.83 | LGALS3 (0.49) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL1302590 | 0.81 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL1303257 | 0.81 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL20852300 | 0.81 | HK2 (0.56) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL24256660 | 0.81 | CA2 (0.60) | MAPK1PYGBCA2CA9ALDH1A1 | |
| SCHEMBL25867393 | 0.81 | CA2 (0.60) | MAPK1PYGBCA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115531554-B | Synthetic lethal nano-drug combination carrier and application thereof in preparation of GBM targeted drugs | 河南大学 | 2023-08-11 | — | — | CN | claimed |
| CN-115531554-A | Synthetic lethal nano-drug combined carrier and application thereof in preparation of GBM targeted drugs | 河南大学 | 2022-12-30 | — | — | CN | claimed |
| JP-10298039-A | — | — | None | — | — | JP | disclosed |
| US-20260002000-A1 | HYBRID POLYMERS AND COMPOSITIONS INCLUDING THE SAME | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2026-01-01 | — | — | US | disclosed |
| US-20250205359-A1 | FERRISILICATE COMPOSITION AND METHOD FOR TREATING INSULIN DEFICIENCY | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-06-26 | — | — | US | disclosed |
| CN-119985995-A | Compositions and methods for detecting traumatic brain injury | 阿米达斯公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12280125-B2 | Method for delivering insulin | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-04-22 | — | — | US | disclosed |
| CN-112424606-B9 | Compositions and methods for detecting traumatic brain injury | 阿米达斯公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-112424606-B | Compositions and methods for detecting traumatic brain injury | 阿米达斯公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240082422-A1 | METHOD FOR DELIVERING INSULIN | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-03-14 | — | — | US | disclosed |
| CN-115531554-A | Synthetic lethal nano-drug combined carrier and application thereof in preparation of GBM targeted drugs | 河南大学 | 2022-12-30 | — | — | CN | disclosed |
| JP-H10298039-A | USE OF 2,3-DIHYDROXYPROPYL 2-(1-OXOALKYL)AMINO-2-DEOXYGLUCOPYRANOSIDE IN DEPILATION THERAPEUTIC AGENT | ELF ATOCHEM SA | 1998-11-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002000-A1 | HYBRID POLYMERS AND COMPOSITIONS INCLUDING THE SAME | H1-3, H1-2, H1-0 | LMNA 1370/4885KDM4E 1469/4885CYP2D6 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.